Trial Profile
Phase IIa, Randomized, Double-blind, Placebo-controlled, 3-period Crossover, Adaptive Dose Design, Clinical Trial to Evaluate Safety & Efficacy of MK0249 in Treating Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome Appropriately Using nCPAP Therapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs MK 0249 (Primary) ; Modafinil
- Indications Sleep apnoea syndrome; Sleep disorders
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Dec 2014 New trial record